share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  06/17 17:30
Moomoo AI 已提取核心信息
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
生物技术临床阶段公司NeuroSense Therapeutics报告称，截至2023年12月31日年度净亏损为1010万美元，去年净亏损为1050万美元。公司的研发费用增加了30.2%，达到730万美元，主要是由于临床研究成本和员工数量增加。总务及管理费用略有下降，为480万美元，下降了3.9%。融资收入净获得190万美元，主要来源于认股权证的再估值。截至2023年12月31日，NeuroSense拥有260万美元的现金和现金等价物。公司的财务报表是基于持续经营的原则编制的，并表示现有资金在未来12个月内将不足以满足资金需求。NeuroSense的领先产品候选PrimeC正在研发中，用于治疗如ALS等神经退行性疾病，并进行持续的临床试验和监管程序。该公司迄今为止尚未产生任何营业收入，并预计将继续投资于产品开发和寻求监管批准，因此将继续出现亏损。
生物技术临床阶段公司NeuroSense Therapeutics报告称，截至2023年12月31日年度净亏损为1010万美元，去年净亏损为1050万美元。公司的研发费用增加了30.2%，达到730万美元，主要是由于临床研究成本和员工数量增加。总务及管理费用略有下降，为480万美元，下降了3.9%。融资收入净获得190万美元，主要来源于认股权证的再估值。截至2023年12月31日，NeuroSense拥有260万美元的现金和现金等价物。公司的财务报表是基于持续经营的原则编制的，并表示现有资金在未来12个月内将不足以满足资金需求。NeuroSense的领先产品候选PrimeC正在研发中，用于治疗如ALS等神经退行性疾病，并进行持续的临床试验和监管程序。该公司迄今为止尚未产生任何营业收入，并预计将继续投资于产品开发和寻求监管批准，因此将继续出现亏损。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息